| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spectroscopy, Near-Infrared | 30 | 2021 | 721 | 4.030 |
Why?
|
| Plaque, Atherosclerotic | 26 | 2022 | 1499 | 2.490 |
Why?
|
| Coronary Artery Disease | 43 | 2022 | 6454 | 2.070 |
Why?
|
| Coronary Vessels | 28 | 2017 | 3099 | 1.820 |
Why?
|
| Myocardial Infarction | 120 | 2022 | 11690 | 1.800 |
Why?
|
| Nuclear Warfare | 2 | 2020 | 31 | 1.430 |
Why?
|
| Lipids | 17 | 2021 | 3302 | 1.210 |
Why?
|
| Circadian Rhythm | 40 | 2006 | 2623 | 1.200 |
Why?
|
| Ultrasonography, Interventional | 16 | 2018 | 1483 | 1.110 |
Why?
|
| Nuclear Weapons | 1 | 2023 | 13 | 0.940 |
Why?
|
| Coronary Disease | 36 | 2020 | 6078 | 0.760 |
Why?
|
| Anger | 9 | 2016 | 402 | 0.750 |
Why?
|
| Global Warming | 1 | 2020 | 63 | 0.700 |
Why?
|
| Physical Exertion | 14 | 2015 | 695 | 0.680 |
Why?
|
| International Cooperation | 3 | 2023 | 1421 | 0.670 |
Why?
|
| Death, Sudden, Cardiac | 20 | 2020 | 1541 | 0.620 |
Why?
|
| Platelet Aggregation | 17 | 2001 | 800 | 0.600 |
Why?
|
| Professional Role | 1 | 2019 | 306 | 0.550 |
Why?
|
| Cardiovascular System | 1 | 2023 | 827 | 0.520 |
Why?
|
| Angioscopy | 6 | 2014 | 49 | 0.510 |
Why?
|
| Multicenter Studies as Topic | 6 | 2017 | 1661 | 0.490 |
Why?
|
| Coronary Angiography | 19 | 2017 | 4567 | 0.480 |
Why?
|
| Cardiovascular Diseases | 29 | 2020 | 15108 | 0.450 |
Why?
|
| Fibrinolysis | 7 | 2001 | 322 | 0.450 |
Why?
|
| Nifedipine | 15 | 1998 | 226 | 0.440 |
Why?
|
| Arteriosclerosis | 7 | 2005 | 1092 | 0.420 |
Why?
|
| Coronary Thrombosis | 10 | 2007 | 494 | 0.390 |
Why?
|
| Coronary Stenosis | 4 | 2010 | 834 | 0.360 |
Why?
|
| Death, Sudden | 9 | 1997 | 298 | 0.360 |
Why?
|
| Atherosclerosis | 9 | 2020 | 3428 | 0.350 |
Why?
|
| Predictive Value of Tests | 20 | 2017 | 15056 | 0.330 |
Why?
|
| Aspirin | 12 | 2020 | 3278 | 0.330 |
Why?
|
| Angioplasty, Balloon, Coronary | 8 | 2014 | 1873 | 0.320 |
Why?
|
| Actins | 1 | 2016 | 2120 | 0.320 |
Why?
|
| Humans | 240 | 2023 | 742088 | 0.310 |
Why?
|
| Rupture, Spontaneous | 6 | 2015 | 354 | 0.310 |
Why?
|
| Photosensitizing Agents | 3 | 2008 | 602 | 0.310 |
Why?
|
| Calcium | 3 | 2018 | 5753 | 0.310 |
Why?
|
| Diagnostic Imaging | 3 | 2010 | 3507 | 0.300 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2016 | 2524 | 0.290 |
Why?
|
| Fiber Optic Technology | 1 | 2008 | 289 | 0.290 |
Why?
|
| Angina, Unstable | 6 | 2021 | 926 | 0.280 |
Why?
|
| Bioterrorism | 4 | 2007 | 143 | 0.280 |
Why?
|
| Angina Pectoris | 15 | 2003 | 977 | 0.270 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 2915 | 0.260 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3130 | 0.260 |
Why?
|
| Electrocardiography | 25 | 2014 | 6440 | 0.260 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3236 | 0.260 |
Why?
|
| Middle Aged | 129 | 2021 | 213127 | 0.260 |
Why?
|
| Stress, Physiological | 3 | 2006 | 1402 | 0.250 |
Why?
|
| Photochemotherapy | 2 | 2008 | 804 | 0.250 |
Why?
|
| Risk Factors | 60 | 2020 | 72145 | 0.250 |
Why?
|
| Heart Arrest | 2 | 2014 | 1469 | 0.240 |
Why?
|
| Sexual Behavior | 4 | 2006 | 2050 | 0.240 |
Why?
|
| Aged | 91 | 2021 | 162944 | 0.230 |
Why?
|
| Risk | 17 | 2016 | 9679 | 0.230 |
Why?
|
| Myocardial Ischemia | 6 | 1999 | 2145 | 0.230 |
Why?
|
| Heart | 8 | 2023 | 4462 | 0.230 |
Why?
|
| Ventricular Fibrillation | 6 | 2007 | 538 | 0.230 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2003 | 176 | 0.220 |
Why?
|
| Catheterization | 1 | 2008 | 1468 | 0.220 |
Why?
|
| Arterial Occlusive Diseases | 3 | 2006 | 793 | 0.220 |
Why?
|
| Marijuana Smoking | 2 | 2008 | 252 | 0.220 |
Why?
|
| Male | 142 | 2021 | 349538 | 0.210 |
Why?
|
| Verapamil | 6 | 2005 | 244 | 0.210 |
Why?
|
| Risk Reduction Behavior | 2 | 2020 | 1123 | 0.210 |
Why?
|
| Fibrosis | 3 | 2015 | 2026 | 0.200 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 6 | 2005 | 281 | 0.200 |
Why?
|
| User-Computer Interface | 1 | 2008 | 1426 | 0.200 |
Why?
|
| Exercise | 9 | 1996 | 5611 | 0.200 |
Why?
|
| Calcinosis | 4 | 2011 | 1497 | 0.200 |
Why?
|
| Spectrum Analysis | 1 | 2003 | 451 | 0.190 |
Why?
|
| Adrenergic beta-Antagonists | 13 | 2013 | 1239 | 0.190 |
Why?
|
| Creatine Kinase | 17 | 2011 | 694 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 9941 | 0.180 |
Why?
|
| Necrosis | 7 | 2015 | 1643 | 0.180 |
Why?
|
| Female | 125 | 2021 | 379592 | 0.180 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2003 | 550 | 0.180 |
Why?
|
| Coronary Circulation | 8 | 2005 | 1572 | 0.180 |
Why?
|
| Prognosis | 31 | 2017 | 29010 | 0.180 |
Why?
|
| Stress, Psychological | 10 | 2012 | 4229 | 0.170 |
Why?
|
| Risk Assessment | 19 | 2020 | 23320 | 0.170 |
Why?
|
| Posture | 7 | 1999 | 958 | 0.170 |
Why?
|
| Fibrinogen | 8 | 2005 | 894 | 0.170 |
Why?
|
| Defibrillators, Implantable | 4 | 2007 | 1440 | 0.170 |
Why?
|
| Tissue Plasminogen Activator | 8 | 2004 | 1262 | 0.170 |
Why?
|
| Membrane Proteins | 1 | 2016 | 7873 | 0.170 |
Why?
|
| Tachycardia, Ventricular | 6 | 2007 | 1272 | 0.170 |
Why?
|
| Sympathetic Nervous System | 2 | 1995 | 514 | 0.160 |
Why?
|
| Prospective Studies | 28 | 2021 | 53187 | 0.160 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 10163 | 0.160 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2003 | 1107 | 0.160 |
Why?
|
| Blood Platelets | 4 | 1992 | 2506 | 0.160 |
Why?
|
| Acute Coronary Syndrome | 3 | 2020 | 2337 | 0.160 |
Why?
|
| Nadolol | 3 | 1994 | 30 | 0.160 |
Why?
|
| Cross-Over Studies | 10 | 2012 | 2030 | 0.150 |
Why?
|
| Tomography, Optical Coherence | 2 | 2017 | 2637 | 0.150 |
Why?
|
| Autopsy | 5 | 2017 | 1006 | 0.150 |
Why?
|
| Weather | 1 | 2018 | 228 | 0.150 |
Why?
|
| Thrombosis | 5 | 2010 | 2966 | 0.150 |
Why?
|
| Hypertension | 13 | 2006 | 8455 | 0.150 |
Why?
|
| Alcohol Drinking | 6 | 2015 | 3957 | 0.140 |
Why?
|
| Vasoconstrictor Agents | 2 | 2001 | 643 | 0.140 |
Why?
|
| Embolism | 2 | 2010 | 409 | 0.140 |
Why?
|
| Anxiety | 3 | 2016 | 4279 | 0.140 |
Why?
|
| Nursing Homes | 2 | 2021 | 1034 | 0.140 |
Why?
|
| Sex | 1 | 1996 | 57 | 0.140 |
Why?
|
| Stents | 6 | 2015 | 3276 | 0.140 |
Why?
|
| Perioperative Care | 1 | 2003 | 997 | 0.130 |
Why?
|
| Carotid Stenosis | 4 | 2006 | 854 | 0.130 |
Why?
|
| Coronary Artery Bypass | 7 | 2016 | 2281 | 0.130 |
Why?
|
| Arrhythmias, Cardiac | 7 | 2006 | 2267 | 0.130 |
Why?
|
| ROC Curve | 3 | 2016 | 3528 | 0.130 |
Why?
|
| Thromboxane A2 | 2 | 1992 | 92 | 0.130 |
Why?
|
| Policy Making | 1 | 2019 | 554 | 0.130 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 4029 | 0.130 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2007 | 156 | 0.130 |
Why?
|
| Syndrome | 4 | 2007 | 3248 | 0.130 |
Why?
|
| Severity of Illness Index | 11 | 2017 | 15530 | 0.120 |
Why?
|
| Tea | 3 | 2006 | 275 | 0.120 |
Why?
|
| Vasodilator Agents | 5 | 2003 | 976 | 0.120 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 552 | 0.120 |
Why?
|
| Alcoholic Beverages | 2 | 2015 | 265 | 0.120 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2017 | 269 | 0.120 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 1995 | 187 | 0.120 |
Why?
|
| Blood Pressure | 17 | 2005 | 8541 | 0.120 |
Why?
|
| Pyridines | 10 | 1983 | 2818 | 0.120 |
Why?
|
| Fibrinolytic Agents | 5 | 1999 | 2156 | 0.120 |
Why?
|
| Aorta | 1 | 2002 | 2057 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2020 | 3067 | 0.120 |
Why?
|
| Public Health | 4 | 2007 | 2594 | 0.120 |
Why?
|
| Hemostasis | 4 | 2005 | 458 | 0.120 |
Why?
|
| Electric Countershock | 3 | 2007 | 535 | 0.120 |
Why?
|
| Educational Status | 4 | 2004 | 2533 | 0.120 |
Why?
|
| Cocaine | 1 | 1999 | 1008 | 0.110 |
Why?
|
| Drug-Eluting Stents | 1 | 2020 | 753 | 0.110 |
Why?
|
| Saphenous Vein | 1 | 2016 | 531 | 0.110 |
Why?
|
| Calcium Channel Blockers | 6 | 2003 | 689 | 0.110 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2016 | 548 | 0.110 |
Why?
|
| Time Factors | 31 | 2015 | 40054 | 0.110 |
Why?
|
| Area Under Curve | 2 | 2016 | 1653 | 0.110 |
Why?
|
| Primary Prevention | 1 | 2020 | 1166 | 0.110 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2001 | 641 | 0.110 |
Why?
|
| Hemodynamics | 8 | 2007 | 4197 | 0.110 |
Why?
|
| Estrogen Replacement Therapy | 2 | 1998 | 1202 | 0.110 |
Why?
|
| Survivors | 3 | 2014 | 2286 | 0.100 |
Why?
|
| Confidence Intervals | 5 | 2015 | 2970 | 0.100 |
Why?
|
| Vascular Resistance | 4 | 1991 | 936 | 0.100 |
Why?
|
| Embolism, Cholesterol | 1 | 2011 | 34 | 0.100 |
Why?
|
| Hyaluronoglucosaminidase | 5 | 1984 | 133 | 0.100 |
Why?
|
| Widowhood | 1 | 2012 | 54 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 3239 | 0.100 |
Why?
|
| Mass Screening | 3 | 2020 | 5238 | 0.100 |
Why?
|
| Coffee | 2 | 2006 | 578 | 0.100 |
Why?
|
| Atenolol | 2 | 2003 | 100 | 0.100 |
Why?
|
| Acute Disease | 9 | 2006 | 7141 | 0.090 |
Why?
|
| Double-Blind Method | 15 | 2008 | 12017 | 0.090 |
Why?
|
| Coronary Vasospasm | 4 | 1983 | 88 | 0.090 |
Why?
|
| Aged, 80 and over | 15 | 2018 | 57683 | 0.090 |
Why?
|
| Ultrasonography | 3 | 2021 | 5978 | 0.090 |
Why?
|
| Adult | 58 | 2015 | 213712 | 0.090 |
Why?
|
| Epinephrine | 8 | 2001 | 793 | 0.090 |
Why?
|
| Antigens, Human Platelet | 2 | 2001 | 43 | 0.090 |
Why?
|
| Interviews as Topic | 4 | 2001 | 2536 | 0.090 |
Why?
|
| Clinical Trials as Topic | 13 | 1999 | 7901 | 0.090 |
Why?
|
| Grief | 1 | 2012 | 247 | 0.090 |
Why?
|
| Cardiology | 1 | 2020 | 1658 | 0.090 |
Why?
|
| Cause of Death | 4 | 2015 | 3571 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1999 | 2276 | 0.080 |
Why?
|
| Case-Control Studies | 7 | 2015 | 21719 | 0.080 |
Why?
|
| Follow-Up Studies | 23 | 2020 | 39004 | 0.080 |
Why?
|
| Diabetic Angiopathies | 2 | 2005 | 820 | 0.080 |
Why?
|
| Angioplasty | 1 | 2011 | 364 | 0.080 |
Why?
|
| Survival Analysis | 9 | 2015 | 10248 | 0.080 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2000 | 187 | 0.080 |
Why?
|
| Adenosine Diphosphate | 7 | 2001 | 425 | 0.080 |
Why?
|
| Drinking Behavior | 2 | 2005 | 103 | 0.080 |
Why?
|
| Factor VII | 4 | 2004 | 139 | 0.080 |
Why?
|
| Hyperlipidemias | 2 | 2006 | 786 | 0.080 |
Why?
|
| Smoking Cessation | 1 | 2020 | 2068 | 0.080 |
Why?
|
| Estrogens | 1 | 1995 | 1562 | 0.080 |
Why?
|
| Antihypertensive Agents | 3 | 2006 | 2043 | 0.080 |
Why?
|
| Angina Pectoris, Variant | 6 | 1983 | 55 | 0.080 |
Why?
|
| Receptors, Scavenger | 1 | 2007 | 121 | 0.080 |
Why?
|
| Dogs | 11 | 1999 | 3910 | 0.070 |
Why?
|
| Incidence | 9 | 2018 | 20928 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2006 | 2013 | 0.070 |
Why?
|
| Heart Rate | 12 | 1997 | 4091 | 0.070 |
Why?
|
| Spironolactone | 1 | 1990 | 382 | 0.070 |
Why?
|
| Digoxin | 3 | 1986 | 250 | 0.070 |
Why?
|
| Recurrence | 10 | 2011 | 8333 | 0.070 |
Why?
|
| Life Change Events | 1 | 2012 | 937 | 0.070 |
Why?
|
| Inflammation | 3 | 2022 | 10578 | 0.070 |
Why?
|
| United States | 21 | 2021 | 69693 | 0.070 |
Why?
|
| Reproducibility of Results | 7 | 2016 | 19862 | 0.070 |
Why?
|
| Emotions | 3 | 2016 | 2657 | 0.070 |
Why?
|
| Pandemics | 3 | 2021 | 8328 | 0.070 |
Why?
|
| Sensitivity and Specificity | 6 | 2005 | 14720 | 0.070 |
Why?
|
| Proportional Hazards Models | 11 | 2015 | 12344 | 0.070 |
Why?
|
| Rupture | 1 | 2007 | 430 | 0.070 |
Why?
|
| Clinical Enzyme Tests | 3 | 1999 | 115 | 0.070 |
Why?
|
| Cohort Studies | 15 | 2015 | 40450 | 0.070 |
Why?
|
| Arousal | 3 | 1999 | 1165 | 0.070 |
Why?
|
| Hemorrhage | 1 | 2017 | 3461 | 0.070 |
Why?
|
| Catecholamines | 2 | 1999 | 387 | 0.070 |
Why?
|
| Serum Albumin, Bovine | 1 | 2006 | 324 | 0.060 |
Why?
|
| Logistic Models | 4 | 2013 | 13403 | 0.060 |
Why?
|
| Prothrombin | 1 | 2005 | 185 | 0.060 |
Why?
|
| Polymorphism, Genetic | 3 | 2001 | 4328 | 0.060 |
Why?
|
| Electrocardiography, Ambulatory | 3 | 1999 | 585 | 0.060 |
Why?
|
| Stroke Volume | 9 | 2004 | 4983 | 0.060 |
Why?
|
| Tablets, Enteric-Coated | 3 | 1997 | 23 | 0.060 |
Why?
|
| Thrombophilia | 2 | 2004 | 305 | 0.060 |
Why?
|
| Sweden | 2 | 2018 | 1343 | 0.060 |
Why?
|
| Disease Models, Animal | 5 | 2007 | 18006 | 0.060 |
Why?
|
| Disease Susceptibility | 3 | 2006 | 1780 | 0.060 |
Why?
|
| Radionuclide Imaging | 4 | 2005 | 2027 | 0.060 |
Why?
|
| Random Allocation | 11 | 1989 | 2425 | 0.060 |
Why?
|
| Microvessels | 1 | 2008 | 544 | 0.060 |
Why?
|
| Coitus | 2 | 2002 | 133 | 0.060 |
Why?
|
| Interview, Psychological | 3 | 2013 | 812 | 0.060 |
Why?
|
| Heart Failure | 11 | 2004 | 10856 | 0.060 |
Why?
|
| Research Design | 3 | 2007 | 5979 | 0.060 |
Why?
|
| Marijuana Abuse | 1 | 2008 | 402 | 0.060 |
Why?
|
| Treatment Outcome | 12 | 2020 | 62966 | 0.060 |
Why?
|
| Porphyrins | 1 | 2006 | 348 | 0.060 |
Why?
|
| Sulfonylurea Compounds | 1 | 2005 | 204 | 0.060 |
Why?
|
| Hydrocortisone | 3 | 1999 | 1825 | 0.060 |
Why?
|
| Prosthesis Design | 1 | 2010 | 2110 | 0.060 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2005 | 319 | 0.060 |
Why?
|
| Carotid Artery, Internal | 1 | 2006 | 445 | 0.060 |
Why?
|
| Epidemiologic Studies | 1 | 2006 | 676 | 0.060 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2003 | 76 | 0.060 |
Why?
|
| Hydrochlorothiazide | 1 | 2003 | 98 | 0.050 |
Why?
|
| Netherlands | 3 | 2012 | 2170 | 0.050 |
Why?
|
| Activities of Daily Living | 2 | 1989 | 2414 | 0.050 |
Why?
|
| Age Factors | 10 | 2016 | 18355 | 0.050 |
Why?
|
| Rabbits | 4 | 2007 | 4886 | 0.050 |
Why?
|
| Automobile Driving | 1 | 2007 | 431 | 0.050 |
Why?
|
| Feasibility Studies | 4 | 2009 | 5062 | 0.050 |
Why?
|
| Isoenzymes | 10 | 1989 | 1725 | 0.050 |
Why?
|
| Radiology, Interventional | 1 | 2006 | 460 | 0.050 |
Why?
|
| Hypolipidemic Agents | 1 | 2006 | 604 | 0.050 |
Why?
|
| Diabetes Complications | 4 | 2001 | 1359 | 0.050 |
Why?
|
| Algorithms | 5 | 2020 | 13853 | 0.050 |
Why?
|
| Vasodilation | 2 | 2005 | 944 | 0.050 |
Why?
|
| Chi-Square Distribution | 3 | 2016 | 3510 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2004 | 2295 | 0.050 |
Why?
|
| Personality Inventory | 2 | 2013 | 1026 | 0.050 |
Why?
|
| Beverages | 1 | 2006 | 820 | 0.050 |
Why?
|
| Vasculitis | 1 | 2005 | 521 | 0.050 |
Why?
|
| Life Style | 2 | 2006 | 3824 | 0.050 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2002 | 247 | 0.050 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2002 | 689 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2006 | 983 | 0.050 |
Why?
|
| Propranolol | 5 | 1989 | 502 | 0.050 |
Why?
|
| Animals | 23 | 2008 | 168561 | 0.050 |
Why?
|
| Terminology as Topic | 2 | 2004 | 1548 | 0.040 |
Why?
|
| Reference Values | 4 | 1999 | 4982 | 0.040 |
Why?
|
| Caffeine | 1 | 2004 | 699 | 0.040 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 12242 | 0.040 |
Why?
|
| Thrombolytic Therapy | 4 | 2002 | 2161 | 0.040 |
Why?
|
| Terrorism | 1 | 2002 | 211 | 0.040 |
Why?
|
| Analysis of Variance | 6 | 2006 | 6365 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2006 | 959 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2002 | 939 | 0.040 |
Why?
|
| Menstrual Cycle | 1 | 2002 | 551 | 0.040 |
Why?
|
| Prostaglandins | 1 | 1999 | 405 | 0.040 |
Why?
|
| Odds Ratio | 5 | 2006 | 9846 | 0.040 |
Why?
|
| Biology | 1 | 2020 | 292 | 0.040 |
Why?
|
| Folic Acid | 1 | 2005 | 1300 | 0.040 |
Why?
|
| Blood Viscosity | 3 | 2005 | 124 | 0.040 |
Why?
|
| Sex Factors | 9 | 2015 | 10392 | 0.040 |
Why?
|
| Nitroglycerin | 5 | 1983 | 325 | 0.040 |
Why?
|
| Time | 2 | 1991 | 530 | 0.040 |
Why?
|
| Postmenopause | 2 | 1998 | 2461 | 0.040 |
Why?
|
| von Willebrand Factor | 4 | 2005 | 668 | 0.040 |
Why?
|
| Platelet Activation | 2 | 1999 | 671 | 0.040 |
Why?
|
| Hypobetalipoproteinemias | 1 | 1997 | 11 | 0.040 |
Why?
|
| Age Distribution | 1 | 2003 | 2900 | 0.040 |
Why?
|
| Myocardial Contraction | 4 | 1983 | 1585 | 0.040 |
Why?
|
| Radiopharmaceuticals | 2 | 2005 | 2658 | 0.040 |
Why?
|
| Massachusetts | 4 | 2001 | 8662 | 0.040 |
Why?
|
| Shock, Cardiogenic | 3 | 1989 | 684 | 0.040 |
Why?
|
| Heparin | 1 | 1984 | 1636 | 0.040 |
Why?
|
| Patient Care | 1 | 2022 | 639 | 0.040 |
Why?
|
| Patient Selection | 2 | 2012 | 4214 | 0.040 |
Why?
|
| Europe | 1 | 2003 | 3339 | 0.040 |
Why?
|
| Norepinephrine | 3 | 1994 | 909 | 0.030 |
Why?
|
| Death | 1 | 2021 | 675 | 0.030 |
Why?
|
| Positron-Emission Tomography | 3 | 2006 | 6259 | 0.030 |
Why?
|
| Tachycardia | 3 | 1987 | 620 | 0.030 |
Why?
|
| Linear Models | 2 | 2012 | 5948 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 3328 | 0.030 |
Why?
|
| Viper Venoms | 1 | 1995 | 14 | 0.030 |
Why?
|
| Suicide, Attempted | 1 | 2004 | 1218 | 0.030 |
Why?
|
| Texas | 1 | 2016 | 392 | 0.030 |
Why?
|
| Enzyme Precursors | 1 | 1995 | 176 | 0.030 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 24913 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 1997 | 373 | 0.030 |
Why?
|
| Michigan | 1 | 2016 | 350 | 0.030 |
Why?
|
| Autonomic Nervous System | 2 | 1997 | 671 | 0.030 |
Why?
|
| Heart Diseases | 2 | 1996 | 2789 | 0.030 |
Why?
|
| Chest Pain | 1 | 2002 | 1113 | 0.030 |
Why?
|
| Body Height | 1 | 2001 | 1574 | 0.030 |
Why?
|
| Embolic Protection Devices | 1 | 2015 | 42 | 0.030 |
Why?
|
| Myocardium | 10 | 2003 | 4775 | 0.030 |
Why?
|
| Physician's Role | 1 | 2002 | 942 | 0.030 |
Why?
|
| Dreams | 1 | 1996 | 147 | 0.030 |
Why?
|
| Public Health Administration | 2 | 2007 | 239 | 0.030 |
Why?
|
| Prevalence | 4 | 2006 | 15194 | 0.030 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2015 | 214 | 0.030 |
Why?
|
| Causality | 1 | 2001 | 1265 | 0.030 |
Why?
|
| Macrophages | 2 | 2006 | 5655 | 0.030 |
Why?
|
| Cholesterol, Dietary | 1 | 1995 | 231 | 0.030 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1995 | 337 | 0.030 |
Why?
|
| Registries | 3 | 2020 | 8077 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2006 | 35342 | 0.030 |
Why?
|
| Diuretics | 2 | 2003 | 591 | 0.030 |
Why?
|
| Emergencies | 1 | 1980 | 1164 | 0.030 |
Why?
|
| Forecasting | 2 | 2020 | 2948 | 0.030 |
Why?
|
| Sleep Stages | 1 | 1997 | 686 | 0.030 |
Why?
|
| Rage | 1 | 2013 | 30 | 0.030 |
Why?
|
| Platelet Count | 3 | 1999 | 780 | 0.030 |
Why?
|
| Vasoconstriction | 3 | 1981 | 596 | 0.030 |
Why?
|
| Mental Processes | 1 | 1994 | 249 | 0.030 |
Why?
|
| Obesity | 3 | 2004 | 12705 | 0.030 |
Why?
|
| Histamine | 1 | 1995 | 507 | 0.030 |
Why?
|
| Data Collection | 1 | 2002 | 3339 | 0.030 |
Why?
|
| Exercise Test | 5 | 1999 | 2075 | 0.030 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 12958 | 0.030 |
Why?
|
| Lipectomy | 1 | 2014 | 118 | 0.030 |
Why?
|
| Comorbidity | 3 | 2004 | 10372 | 0.030 |
Why?
|
| Galvanic Skin Response | 1 | 1994 | 349 | 0.030 |
Why?
|
| Retrospective Studies | 11 | 2020 | 77098 | 0.030 |
Why?
|
| Advisory Committees | 2 | 2007 | 773 | 0.030 |
Why?
|
| Diabetes Mellitus | 5 | 2004 | 5724 | 0.030 |
Why?
|
| Insulin | 4 | 2005 | 6575 | 0.030 |
Why?
|
| Fluorescein Angiography | 1 | 2017 | 936 | 0.030 |
Why?
|
| Sleep, REM | 1 | 1996 | 594 | 0.030 |
Why?
|
| Demography | 3 | 2004 | 1650 | 0.030 |
Why?
|
| Survival Rate | 4 | 2014 | 12773 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2002 | 3760 | 0.030 |
Why?
|
| Statistics, Nonparametric | 3 | 2006 | 2885 | 0.030 |
Why?
|
| Streptokinase | 2 | 1983 | 188 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2005 | 3748 | 0.030 |
Why?
|
| Receptors, Adrenergic | 1 | 1992 | 155 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 2 | 1989 | 1499 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2015 | 8297 | 0.030 |
Why?
|
| Sleep | 3 | 1997 | 4604 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 1887 | 0.020 |
Why?
|
| Propanolamines | 1 | 1992 | 167 | 0.020 |
Why?
|
| Delayed-Action Preparations | 3 | 2003 | 965 | 0.020 |
Why?
|
| Tissue Distribution | 2 | 2006 | 2335 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 1996 | 1364 | 0.020 |
Why?
|
| Epoprostenol | 1 | 1992 | 254 | 0.020 |
Why?
|
| Estradiol | 1 | 1998 | 2021 | 0.020 |
Why?
|
| Premenopause | 1 | 1995 | 1033 | 0.020 |
Why?
|
| Ventricular Function, Left | 2 | 1995 | 3656 | 0.020 |
Why?
|
| Fear | 1 | 1999 | 1436 | 0.020 |
Why?
|
| Nuclear Family | 1 | 2012 | 318 | 0.020 |
Why?
|
| Organ Specificity | 2 | 2006 | 2003 | 0.020 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2020 | 1181 | 0.020 |
Why?
|
| No-Reflow Phenomenon | 1 | 2009 | 14 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2004 | 6891 | 0.020 |
Why?
|
| Carbazoles | 1 | 1992 | 226 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2016 | 2372 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2004 | 12695 | 0.020 |
Why?
|
| Heart Rupture | 1 | 1989 | 23 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2011 | 15244 | 0.020 |
Why?
|
| Thrombectomy | 1 | 2014 | 679 | 0.020 |
Why?
|
| Electrolytes | 1 | 1990 | 282 | 0.020 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 1989 | 49 | 0.020 |
Why?
|
| Hospitalization | 9 | 2013 | 10232 | 0.020 |
Why?
|
| Hematocrit | 2 | 1988 | 636 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 1996 | 904 | 0.020 |
Why?
|
| Metoprolol | 1 | 1989 | 93 | 0.020 |
Why?
|
| Wakefulness | 1 | 1995 | 1243 | 0.020 |
Why?
|
| Actuarial Analysis | 2 | 2004 | 377 | 0.020 |
Why?
|
| Smoking | 6 | 2004 | 8969 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 1990 | 486 | 0.020 |
Why?
|
| Drug Therapy, Combination | 3 | 1990 | 6483 | 0.020 |
Why?
|
| History, 19th Century | 2 | 1983 | 720 | 0.020 |
Why?
|
| Myocardial Revascularization | 1 | 2012 | 841 | 0.020 |
Why?
|
| Placebos | 3 | 1996 | 1677 | 0.020 |
Why?
|
| Regional Blood Flow | 4 | 2005 | 1525 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 1998 | 2059 | 0.020 |
Why?
|
| Oxygen Consumption | 4 | 1983 | 1869 | 0.020 |
Why?
|
| Air Pollution | 1 | 2001 | 2284 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2011 | 20086 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2001 | 780 | 0.020 |
Why?
|
| Pericarditis | 1 | 1989 | 128 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 1997 | 2354 | 0.020 |
Why?
|
| Fluorocarbons | 2 | 1983 | 452 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 1991 | 1589 | 0.020 |
Why?
|
| Troponin I | 1 | 2011 | 619 | 0.020 |
Why?
|
| Aging | 1 | 2005 | 8626 | 0.020 |
Why?
|
| Stroke | 2 | 2006 | 9963 | 0.020 |
Why?
|
| Chlorophyllides | 1 | 2006 | 53 | 0.020 |
Why?
|
| Bundle-Branch Block | 1 | 1988 | 270 | 0.020 |
Why?
|
| Tissue Polypeptide Antigen | 1 | 2005 | 4 | 0.020 |
Why?
|
| Death Certificates | 1 | 1987 | 169 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 3070 | 0.020 |
Why?
|
| Injections, Intravenous | 3 | 1983 | 1420 | 0.020 |
Why?
|
| Age of Onset | 2 | 2003 | 3266 | 0.020 |
Why?
|
| Cholesterol | 1 | 1995 | 2895 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2006 | 379 | 0.020 |
Why?
|
| Centrifugation | 1 | 2005 | 122 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2002 | 4250 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2016 | 2684 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2005 | 288 | 0.020 |
Why?
|
| Swine | 2 | 2007 | 5934 | 0.020 |
Why?
|
| Nitrates | 2 | 1984 | 265 | 0.020 |
Why?
|
| Research | 1 | 1994 | 1999 | 0.020 |
Why?
|
| Women | 1 | 1987 | 230 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2010 | 899 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2004 | 6874 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2009 | 1849 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 1999 | 3258 | 0.020 |
Why?
|
| Cold Temperature | 3 | 1983 | 774 | 0.020 |
Why?
|
| Heart Block | 1 | 1986 | 410 | 0.020 |
Why?
|
| Patient Compliance | 2 | 2005 | 2680 | 0.010 |
Why?
|
| Psychometrics | 1 | 2013 | 2999 | 0.010 |
Why?
|
| Medicare | 1 | 2021 | 6532 | 0.010 |
Why?
|
| Diltiazem | 2 | 1980 | 133 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 1991 | 1827 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2006 | 10943 | 0.010 |
Why?
|
| Sleep Deprivation | 1 | 1990 | 830 | 0.010 |
Why?
|
| Colorimetry | 1 | 2004 | 147 | 0.010 |
Why?
|
| Eating | 1 | 1990 | 1535 | 0.010 |
Why?
|
| Carbonated Beverages | 1 | 2004 | 214 | 0.010 |
Why?
|
| Motor Activity | 1 | 2013 | 2714 | 0.010 |
Why?
|
| Waist-Hip Ratio | 1 | 2004 | 517 | 0.010 |
Why?
|
| Emergency Medical Services | 2 | 2002 | 1914 | 0.010 |
Why?
|
| History, 20th Century | 2 | 1983 | 2739 | 0.010 |
Why?
|
| Diastole | 2 | 1998 | 791 | 0.010 |
Why?
|
| Nuclear Medicine | 1 | 2005 | 233 | 0.010 |
Why?
|
| Markov Chains | 1 | 2005 | 969 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 3 | 1988 | 1676 | 0.010 |
Why?
|
| Philosophy, Medical | 1 | 2002 | 79 | 0.010 |
Why?
|
| Follicular Phase | 1 | 2002 | 153 | 0.010 |
Why?
|
| Africa | 1 | 2004 | 670 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 1969 | 0.010 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 1983 | 219 | 0.010 |
Why?
|
| Health Care Costs | 1 | 1995 | 3203 | 0.010 |
Why?
|
| Heart Function Tests | 2 | 1996 | 330 | 0.010 |
Why?
|
| Perhexiline | 1 | 1980 | 5 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2005 | 1423 | 0.010 |
Why?
|
| Integrin beta3 | 1 | 2001 | 122 | 0.010 |
Why?
|
| Equipment Design | 1 | 2009 | 3582 | 0.010 |
Why?
|
| Disease Progression | 2 | 2010 | 13256 | 0.010 |
Why?
|
| Regression Analysis | 2 | 1992 | 6452 | 0.010 |
Why?
|
| Oxygen | 2 | 1983 | 4169 | 0.010 |
Why?
|
| Family | 1 | 2012 | 3144 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1983 | 853 | 0.010 |
Why?
|
| False Negative Reactions | 3 | 1988 | 587 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2006 | 1961 | 0.010 |
Why?
|
| Cattle | 2 | 2004 | 3923 | 0.010 |
Why?
|
| Embolization, Therapeutic | 1 | 2010 | 1392 | 0.010 |
Why?
|
| Adenosine | 1 | 2005 | 823 | 0.010 |
Why?
|
| Drug Administration Schedule | 2 | 1998 | 4929 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 1983 | 535 | 0.010 |
Why?
|
| Congresses as Topic | 1 | 2004 | 764 | 0.010 |
Why?
|
| False Positive Reactions | 3 | 1988 | 981 | 0.010 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2005 | 1679 | 0.010 |
Why?
|
| Family Health | 1 | 2004 | 1282 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 2382 | 0.010 |
Why?
|
| Medical Records | 1 | 2004 | 1413 | 0.010 |
Why?
|
| Potassium | 1 | 1983 | 1336 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1978 | 326 | 0.010 |
Why?
|
| Benzazepines | 1 | 1980 | 326 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 3862 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 2003 | 994 | 0.010 |
Why?
|
| USSR | 1 | 1977 | 21 | 0.010 |
Why?
|
| Heart Aneurysm | 1 | 1978 | 120 | 0.010 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 1997 | 83 | 0.010 |
Why?
|
| Carotid Arteries | 1 | 2002 | 952 | 0.010 |
Why?
|
| Cardiovascular Agents | 1 | 2004 | 848 | 0.010 |
Why?
|
| Carbon | 1 | 2001 | 686 | 0.010 |
Why?
|
| Hyaluronic Acid | 1 | 1981 | 489 | 0.010 |
Why?
|
| Longitudinal Studies | 2 | 1997 | 13921 | 0.010 |
Why?
|
| Particle Size | 1 | 2001 | 1640 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2012 | 5100 | 0.010 |
Why?
|
| Heart Ventricles | 5 | 1989 | 3801 | 0.010 |
Why?
|
| Long QT Syndrome | 1 | 2001 | 453 | 0.010 |
Why?
|
| Homozygote | 1 | 2001 | 1777 | 0.010 |
Why?
|
| Progestins | 1 | 1998 | 303 | 0.010 |
Why?
|
| Systole | 1 | 1998 | 956 | 0.010 |
Why?
|
| Fourier Analysis | 1 | 1997 | 447 | 0.010 |
Why?
|
| Cardiopulmonary Bypass | 2 | 1978 | 1066 | 0.010 |
Why?
|
| Heart Arrest, Induced | 1 | 1977 | 355 | 0.010 |
Why?
|
| Genotype | 2 | 2001 | 12946 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 2 | 2005 | 5385 | 0.010 |
Why?
|
| Monitoring, Physiologic | 2 | 1997 | 1737 | 0.010 |
Why?
|
| Ion Channels | 1 | 1980 | 1056 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2001 | 2422 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 13019 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2005 | 1384 | 0.010 |
Why?
|
| Seasons | 1 | 2001 | 1492 | 0.010 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2002 | 1440 | 0.010 |
Why?
|
| Isoproterenol | 1 | 1975 | 399 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2006 | 2921 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2005 | 6030 | 0.010 |
Why?
|
| Thorax | 1 | 1978 | 547 | 0.010 |
Why?
|
| Epitopes | 1 | 2001 | 2569 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2006 | 2217 | 0.010 |
Why?
|
| Consensus | 1 | 2003 | 2935 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2001 | 3587 | 0.010 |
Why?
|
| Mortality | 1 | 2005 | 2857 | 0.010 |
Why?
|
| Action Potentials | 2 | 1980 | 1814 | 0.010 |
Why?
|
| Glycolysis | 1 | 1978 | 825 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 11363 | 0.010 |
Why?
|
| Phenotype | 2 | 2001 | 16331 | 0.010 |
Why?
|
| Polymers | 1 | 1981 | 1618 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2004 | 2616 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1984 | 3800 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1983 | 1788 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1978 | 633 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2005 | 2866 | 0.010 |
Why?
|
| Vascular Patency | 1 | 1995 | 885 | 0.010 |
Why?
|
| Yohimbine | 1 | 1992 | 62 | 0.010 |
Why?
|
| Heart Valve Diseases | 1 | 2000 | 1067 | 0.010 |
Why?
|
| Piperidines | 1 | 1980 | 1602 | 0.010 |
Why?
|
| Hypothermia, Induced | 1 | 1977 | 747 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1992 | 1159 | 0.010 |
Why?
|
| Glucose | 1 | 1983 | 4391 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 1997 | 1813 | 0.010 |
Why?
|
| Probability | 2 | 1987 | 2502 | 0.010 |
Why?
|
| Alleles | 1 | 2001 | 6931 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2001 | 17400 | 0.010 |
Why?
|
| Adolescent | 4 | 2004 | 85649 | 0.010 |
Why?
|
| Triglycerides | 1 | 1997 | 2450 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2001 | 3439 | 0.010 |
Why?
|
| Heart Septum | 1 | 1989 | 313 | 0.000 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 7276 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 13814 | 0.000 |
Why?
|
| Anticoagulants | 1 | 1983 | 4595 | 0.000 |
Why?
|
| Collagen | 1 | 1996 | 2684 | 0.000 |
Why?
|
| Models, Biological | 1 | 2004 | 9581 | 0.000 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 8925 | 0.000 |
Why?
|
| Mutation | 2 | 2001 | 29717 | 0.000 |
Why?
|
| Renin | 1 | 1988 | 642 | 0.000 |
Why?
|
| Rats | 2 | 1983 | 24265 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 6608 | 0.000 |
Why?
|
| Diphosphates | 1 | 1985 | 88 | 0.000 |
Why?
|
| Angiotensin II | 1 | 1988 | 881 | 0.000 |
Why?
|
| Bradycardia | 1 | 1986 | 305 | 0.000 |
Why?
|
| Sodium Pertechnetate Tc 99m | 1 | 1983 | 57 | 0.000 |
Why?
|
| Mathematics | 1 | 1985 | 727 | 0.000 |
Why?
|
| Technetium | 1 | 1983 | 334 | 0.000 |
Why?
|
| Methods | 1 | 1983 | 1128 | 0.000 |
Why?
|
| Ambulatory Care | 1 | 1994 | 2706 | 0.000 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1986 | 790 | 0.000 |
Why?
|
| Phentolamine | 1 | 1981 | 104 | 0.000 |
Why?
|
| Blood Gas Analysis | 1 | 1982 | 381 | 0.000 |
Why?
|
| Pressoreceptors | 1 | 1981 | 100 | 0.000 |
Why?
|
| Hypotension | 1 | 1986 | 880 | 0.000 |
Why?
|
| Nitrogen | 1 | 1980 | 343 | 0.000 |
Why?
|
| Spasm | 1 | 1979 | 121 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1980 | 1386 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1981 | 2255 | 0.000 |
Why?
|
| Electrophysiology | 1 | 1980 | 1309 | 0.000 |
Why?
|
| Biological Transport | 1 | 1982 | 2119 | 0.000 |
Why?
|
| Kidney Diseases | 1 | 1988 | 2145 | 0.000 |
Why?
|
| Injections, Intradermal | 1 | 1977 | 117 | 0.000 |
Why?
|
| Testis | 1 | 1981 | 800 | 0.000 |
Why?
|
| Cyclic AMP | 1 | 1980 | 1470 | 0.000 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1977 | 424 | 0.000 |
Why?
|
| Aspartate Aminotransferases | 1 | 1977 | 418 | 0.000 |
Why?
|
| Child | 1 | 2004 | 77478 | 0.000 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 1979 | 846 | 0.000 |
Why?
|
| Sodium | 1 | 1980 | 1627 | 0.000 |
Why?
|
| Heart Conduction System | 1 | 1980 | 1048 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1981 | 1355 | 0.000 |
Why?
|
| Adenosine Triphosphate | 1 | 1980 | 2024 | 0.000 |
Why?
|
| Infant | 1 | 1996 | 35070 | 0.000 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1976 | 1372 | 0.000 |
Why?
|